We are live on ! Find out more
CCMU

Cheyne Capital Management (UK) Portfolio holdings

AUM $27.9M
1-Year Est. Return 36.14%
This Fund
S&P 500
This Quarter Est. Return
+4.67%
1 Year Est. Return
+36.14%
3 Year Est. Return
+35.61%
5 Year Est. Return
+211.68%
10 Year Est. Return
+661.99%
AUM
$57.2M
AUM Growth
+$10.5M
Cap. Flow
+$11.3M
Cap. Flow %
19.68%
Top 10 Hldgs %
46.43%
Holding
72
New
39
Increased
1
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$1.61M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$1.55M
3
RAPT
RAPT Therapeutics
RAPT
+$1.44M
4
PLRX icon
Pliant Therapeutics
PLRX
+$1.38M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$1.16M

Top Sells

Rank Stock Value
1
SWCH
Switch, Inc. Class A Common Stock
SWCH
+$4.41M
2
CRWD icon
CrowdStrike
CRWD
+$2.04M
3
ATVI
Activision Blizzard
ATVI
+$963K
4
FTCH
Farfetch Limited Class A Ordinary Shares
FTCH
+$844K
5
RDNT icon
RadNet
RDNT
+$601K

Sector Composition

Rank Sector Weight
1 Healthcare 41.62%
2 Energy 19.93%
3 Technology 17.56%
4 Materials 10.23%
5 Consumer Discretionary 3.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
26
Aclaris Therapeutics
ACRS
$825M
$803K 1.4%
+50,964
New +$820K
HRTX icon
27
Heron Therapeutics
HRTX
$92.9M
$795K 1.39%
+318,008
New +$1.02M
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.55B
$793K 1.39%
+17,115
New +$673K
OPTN
29
DELISTED
OptiNose
OPTN
$730K 1.28%
+26,316
New +$999K
UBER icon
30
Uber
UBER
$153B
$722K 1.26%
29,200
– –
VTYX
31
DELISTED
Ventyx Biosciences
VTYX
$657K 1.15%
+20,035
New +$593K
VKTX icon
32
Viking Therapeutics
VKTX
$4B
$609K 1.06%
+64,753
New +$289K
DAWN
33
DELISTED
Day One Biopharmaceuticals
DAWN
$586K 1.02%
+27,223
New +$558K
CCJ icon
34
Cameco
CCJ
$42.4B
$583K 1.02%
25,700
– –
PTCT icon
35
PTC Therapeutics
PTCT
$6.12B
$577K 1.01%
+15,106
New +$628K
JBIO
36
Jade Biosciences
JBIO
$1.34B
$555K 0.97%
+541
New +$393K
OXY icon
37
CALL
Occidental Petroleum
OXY
$55.9B
$536K 0.94%
+302
New +$20.6K
PAAS icon
38
Pan American Silver
PAAS
$21.6B
$503K 0.88%
30,800
– –
TVTX icon
39
Travere Therapeutics
TVTX
$5.78B
$499K 0.87%
+23,750
New +$503K
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$486K 0.85%
+77,499
New +$295K
SRPT icon
41
Sarepta Therapeutics
SRPT
$1.77B
$473K 0.83%
+3,650
New +$423K
EQT icon
42
EQT Corp
EQT
$32.3B
$413K 0.72%
+12,200
New +$490K
KALV
43
DELISTED
KalVista Pharmaceuticals
KALV
$357K 0.62%
+52,790
New +$283K
AMLX icon
44
Amylyx Pharmaceuticals
AMLX
$2.54B
$351K 0.61%
+9,499
New +$337K
MLTX icon
45
MoonLake Immunotherapeutics
MLTX
$1.55B
$337K 0.59%
+32,129
New +$286K
ICPT
46
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$327K 0.57%
+26,443
New +$374K
ABOS icon
47
Acumen Pharmaceuticals
ABOS
$176M
$301K 0.53%
+55,829
New +$375K
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$301K 0.53%
+6,650
New +$430K
VERV
49
DELISTED
Verve Therapeutics
VERV
$290K 0.51%
+15,000
New +$397K
ALBO
50
DELISTED
Albireo Pharma Inc
ALBO
$289K 0.5%
+13,364
New +$282K
1
2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return
TCM
TORQ Capital Management Hong Kong $38.1M AUM 2.81% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
AMC
AKKR Management Company Menlo Park, California $42.5M AUM 123.1% 1-Year Est. Return
P
Pariax Newport Beach, California $44.3M AUM 12.57% 1-Year Est. Return
AOGP
Addition One General Partner New York $45.7M AUM
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Cheyne Capital Management (UK)'s Q4 2022 Portfolio in Review

As of Q4 2022, Cheyne Capital Management (UK) held 72 positions worth $57.2M, up 22% from $46.8M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cheyne Capital Management (UK) deployed $11.3M of net new capital in Q4 2022, opening 39 new positions and adding to 1 existing holding. Its largest new stake was CinCor Pharma, Inc. Common Stock: 67,557 shares worth $830K.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 6.4% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was Activision Blizzard, an estimated $963K trimmed.

  • Cheyne Capital Management (UK)'s largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 67,557 shares worth $830K.
  • Cheyne Capital Management (UK) added most to Expand Energy Corp in Q4 2022, an estimated $84.8K increase.
  • Cheyne Capital Management (UK)'s biggest Q4 2022 reduction was Activision Blizzard, cutting an estimated $963K.
  • Cheyne Capital Management (UK) fully exited Switch, Inc. Class A Common Stock in Q4 2022, selling an estimated $4.41M.
  • Cheyne Capital Management (UK)'s ten largest holdings make up 46% of its $57.2M portfolio in Q4 2022.
  • Cheyne Capital Management (UK) opened 39 new positions and closed 13 in Q4 2022.
  • Cheyne Capital Management (UK)'s portfolio value rose 22% quarter-over-quarter to $57.2M.

Based on Cheyne Capital Management (UK)'s 13F filing for Q4 2022, filed 10 Feb 2023.